211096-49-0

211096-49-0 structure

Name: SB 265610
Chemical Name: 1-(2-bromophenyl)-3-(7-cyano-2H-benzotriazol-4-yl)urea
CAS Number: 211096-49-0
Molecular Formula: C₁₄H₉BrN₆O
Molecular Weight: 357.16500
Catalog: Signaling Pathways GPCR/G Protein CXCR
Create Date: 2016-03-11 18:08:03
Modify Date: 2026-07-02 08:01:38
SB-265610 is a selective, competitive, nonpeptide and allosteric CXCR2 antagonist. SB-265610 blocks rat cytokine-induced neutrophil chemoattractant-1 (CINC-1)-induced calcium mobilization and neutrophil chemotaxis with IC50s of 3.7 nM and 70 nM, respectively[1][2].

Name	1-(2-bromophenyl)-3-(7-cyano-2H-benzotriazol-4-yl)urea
Synonyms	SB 265610 ，S9516 GSK-CXCR2 SB-265610, 10 mM in DMSO 1-(2-Bromophenyl)-3-(4-cyano-1H-benzo[d] [1,2,3]triazol-7-yl)urea Urea, N-(2-bromophenyl)-N'-(4-cyano-1H-benzotriazol-7-yl) CXCR,nonptide,inhibit,Inhibitor,SB-265610,inflammation,recruitment,Delay,SB 265610,healing,neutrophil,SB265610,wound,CXC chemokine rectors N-(2-Bromophenyl)-N'-(7-cyano-1H-benzotriazol-4-yl)urea SB265610 >= (HPLC)

Description	SB-265610 is a selective, competitive, nonpeptide and allosteric CXCR2 antagonist. SB-265610 blocks rat cytokine-induced neutrophil chemoattractant-1 (CINC-1)-induced calcium mobilization and neutrophil chemotaxis with IC50s of 3.7 nM and 70 nM, respectively[1][2].
Related Catalog	Signaling Pathways >> GPCR/G Protein >> CXCR Research Areas >> Inflammation/Immunology Signaling Pathways >> Immunology/Inflammation >> CXCR
Target	CXCR2
In Vitro	In vitro, SB-265610 antagonizes rat cytokine-induced neutrophil chemoattractant-1 (CINC-1)-induced calcium mobilization, IC50 of 3.7 nM, and rat neutrophil chemotaxis in a concentration-dependent manner, IC50 of 70 nM. SB-265610 reduces the antiapoptotic effect of CINC-1 to the levels of those untreated with CINC-1[1].
In Vivo	SB-265610 (100 mg/kg/day; oral administration; daily; for 5 days; CXCR2 wild type mice) treatment during the wound repair process markedly delays healing parameters in CXCR2 wild type mice[2]. Animal Model: Wild type mice with nitrogen mustard[2] Dosage: 100 mg/kg/day Administration: Oral administration; daily; for 5 days Result: Markedly impaired the wound healing process.
References	[1]. Auten RL, et al. Nonpeptide CXCR2 antagonist prevents neutrophil accumulation in hyperoxia-exposed newborn rats. J Pharmacol Exp Ther. 2001 Oct;299(1):90-5. [2]. Milatovic S, et al. Impaired healing of nitrogen mustard wounds in CXCR2 null mice. Wound Repair Regen. 2003 May-Jun;11(3):213-9.

Symbol	GHS07
Signal Word	Warning
Hazard Statements	H302
RIDADR	NONH for all modes of transport